The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

The new approach recommends focusing on quality of life and mental health — and even includes medications like GLP-1s, which ...

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP ...

The two obesity market leaders, with their blockbuster injectables, have left room for an oral, or pill, market to be a new meaningful target for newer players, according to investors. Lilly is the ...

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper supervision, and a protein-rich diet, the results of a new study suggest.

So far this year, Pfizer shares have dropped 17.4% through Friday, while Novo Nordisk's stock has tumbled 24.8% and Lilly shares have slipped 5.1%. The SPDR S&P Pharmaceuticals ETF XPH has shed 12.4% ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

A new Canadian guideline urges lifestyle interventions for obese children but also says today's new drugs might help kids ...

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

As discussions unfold, Kennedy seeks to balance drug accessibility with concerns about the long-term costs of providing GLP-1 ...

Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...